SER
AgeX Therapeutics Inc (SER)
Healthcare • NYSE MKT • $1.75-3.31%
- Symbol
- SER
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.75
- Daily Change
- -3.31%
- Market Cap
- $26.07M
- Trailing P/E
- N/A
- Forward P/E
- -1.67
- 52W High
- $7.92
- 52W Low
- $1.22
- Analyst Target
- $11.00
- Dividend Yield
- N/A
- Beta
- 0.04
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Company websiteResearch SER on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.